Search for: "CELGENE"
Results 61 - 80
of 183
Sort by Relevance
|
Sort by Date
10 Feb 2019, 9:38 pm
February 11, 2019 - "The Next Billion-Dollar Acquisition in Pharma -- A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene" (LexisNexis) - 2:00 pm (ET) February 12, 2019 - "Biotech Patents and Section 101 Rejections: Meeting Patent Eligibility Requirements -- Leveraging Recent Decisions and USPTO Guidance to Overcome Rejections" (Strafford) - 1:00 to 2:30 pm (EST) February 14, 2019 - "Section 112 Issues in IPR Proceedings: Using Section 112 as… [read post]
9 Feb 2019, 9:50 pm
LexisNexis will be offering a webinar on "The Next Billion-Dollar Acquisition in Pharma -- A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene" on February 11, 2019 at 2:00 pm (ET). [read post]
30 Jan 2019, 5:44 am
M&A being lumpy and unpredictable as ever, 2019 has opened with a number of notable deals, not least the sale of Celgene to Bristol-Myers Squibb for $95 billion, somewhat defying gloomy predictions for the year. [read post]
29 Jan 2019, 3:12 pm
Several large cases account for much of this effect, including the cases filed against Johnson & Johnson, Facebood, NVIDIA, Bristol-Myers Squibb and Celgene. [read post]
25 Jan 2019, 12:00 am
The first being Bristol Myers Squibb Co’s (BMY) acquisition of Celgene Corp. [read post]
24 Jan 2019, 2:59 am
Chuck Grassley criticizing Barr, including Harvard Law School Professor Nancy Gertner, participated in litigation against Celgene that the government declined to join but nevertheless generated $280 million in settlements and more than $30 million in legal fees. [read post]
12 Jan 2019, 10:12 am
On January 11, 2019, Congressman Peter Welch and Francis Rooney, members of Congress, wrote a letter to the Federal Trade Commission (“FTC”), urging the Commission to investigate Bristol-Myers Squibb’s (“BMS”) acquisition of Celgene. [read post]
3 Jan 2019, 12:01 pm
The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly oncology. [read post]
15 Jul 2018, 8:44 pm
Celgene Corp. v. [read post]
25 Jun 2018, 3:49 am
In doing so, the courts used to rely on Bolar Principle interpreting such clearly profit-driven actions as registration of price to be preparatory actions that cannot bear threat of infringement (Celgene Corporation vs. [read post]
31 May 2018, 9:50 am
Pfizer is now among a group of multiple drug companies (Celgene Corp., Aegerion Pharmaceuticals, and Jazz Pharmaceuticals) who have settled with the Department of Justice for their use of patient assistance charities. [read post]
31 May 2018, 9:50 am
Pfizer is now among a group of multiple drug companies (Celgene Corp., Aegerion Pharmaceuticals, and Jazz Pharmaceuticals) who have settled with the Department of Justice for their use of patient assistance charities. [read post]
30 May 2018, 2:00 pm
Interestingly, a New York Times article describes Celgene’s response, here. [read post]
22 May 2018, 12:47 pm
But their makers need large batches of Big Pharma samples to work with to develop generics ─ and more than three dozen major firms like Johnson & Johnson’s Actelion Pharmaceuticals, Celgene, Gilead Life Sciences, Novartis, Pfizer, and Valeant have balked at providing requested products. [read post]
2 May 2018, 2:15 pm
Celgene is selling part of its share in CRISPR Therapeutics.From FiercePharma:Bill Lundberg, M.D., has stepped down as CSO of CRISPR Therapeutics. [read post]
21 Nov 2017, 6:15 am
Celgene faces a new gang of generics moving in on its blockbuster Revlimid®. [read post]
21 Nov 2017, 6:15 am
Celgene faces a new gang of generics moving in on its blockbuster Revlimid®. [read post]
16 Nov 2017, 6:17 am
Company Name Annual Director Retainer Regeneron Pharmaceuticals $2,074,085 Tesla $1,664,928 The Goldman Sachs Group $575,000 Salesforce.com $550,000 Celgene Corporation $524,871 Reynolds American $496,480 Valeant Pharmaceuticals International $475,000 Allergan PLC $450,000 Everest Re Group, Ltd. $447,030 Oracle $429,172 (more…) [read post]
3 Aug 2017, 8:15 am
Take for example the $280 million that Celgene has agreed to pay to settle fraud claims over its marketing of Thalomid and Revlimid for unapproved uses. [read post]
28 Jul 2017, 5:14 am
Celgene Corp. [read post]
